EVA is registered trademark of Stern Stewart.
Economic value added or economic profit is the difference between revenues and costs,where costs include not only expenses, but also cost of capital.
Paying user area
Try for free
AbbVie Inc. pages available for free this week:
- Analysis of Profitability Ratios
- Analysis of Liquidity Ratios
- Analysis of Solvency Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Common Stock Valuation Ratios
- Operating Profit Margin since 2012
- Return on Equity (ROE) since 2012
- Return on Assets (ROA) since 2012
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Economic Profit
12 months ended: | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
---|---|---|---|---|---|---|
Net operating profit after taxes (NOPAT)1 | ||||||
Cost of capital2 | ||||||
Invested capital3 | ||||||
Economic profit4 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 NOPAT. See details »
2 Cost of capital. See details »
3 Invested capital. See details »
4 2024 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= – × =
- Net Operating Profit After Taxes (NOPAT)
- The NOPAT experienced significant fluctuations over the five-year period. It more than doubled from 4,455 million USD in 2020 to a peak of 12,362 million USD in 2021, indicating a strong operational performance improvement during this period. However, NOPAT declined slightly in 2022 to 11,543 million USD, followed by a sharp decrease to 3,292 million USD in 2023. By 2024, there was some recovery with NOPAT rising to 4,563 million USD, though it remained well below the peak level observed in 2021.
- Cost of Capital
- The cost of capital demonstrated a steady upward trend throughout the period. Starting at 7.84% in 2020, it rose consistently each year, reaching 9.51% by 2024. This gradual increase indicates a rising required return for investing capital in the company, which may have implications for investment and valuation decisions.
- Invested Capital
- Invested capital showed a continuous decline from 103,725 million USD in 2020 to 68,204 million USD in 2023, a substantial reduction of approximately 34.3%. In 2024, invested capital slightly increased to 69,263 million USD, suggesting a possible stabilization after the prior reductions. The overall reduction in invested capital could reflect divestitures, asset sales, or shifts in investment strategy.
- Economic Profit
- Economic profit fluctuated in close alignment with movements in NOPAT and cost of capital effects. It was negative at -3,673 million USD in 2020, turned positive with a peak of 4,064 million USD in 2021, and remained positive at 3,942 million USD in 2022. This was followed by a steep reversal to negative values of -3,166 million USD in 2023 and -2,027 million USD in 2024. The shift from positive to negative economic profit in later years reflects challenges in generating returns above the cost of capital despite reductions in invested capital.
- Overall Insights
- The company demonstrated strong profitability growth in the early part of the period, with NOPAT and economic profit peaking in 2021. However, rising cost of capital and declining invested capital corresponded with a sharp downturn in profitability and economic profit in subsequent years. The rebound in NOPAT in 2024 has not translated into economic profit recovery, indicating ongoing pressure from elevated capital costs or operational challenges. Strategic attention may be required to address these performance pressures and to enhance value creation relative to capital employed.
Net Operating Profit after Taxes (NOPAT)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Elimination of deferred tax expense. See details »
2 Addition of increase (decrease) in restructuring reserve.
3 Addition of increase (decrease) in equity equivalents to net earnings attributable to AbbVie Inc..
4 2024 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =
5 2024 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =
6 Addition of after taxes interest expense to net earnings attributable to AbbVie Inc..
7 2024 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =
8 Elimination of after taxes investment income.
The financial data reveals significant fluctuations in key profitability metrics over the five-year period from 2020 to 2024. Net earnings attributable to the company show a marked increase between 2020 and 2021, more than doubling from 4,616 million USD to 11,542 million USD. This upward trend continued slightly into 2022, reaching 11,836 million USD. However, a sharp decline is observed in 2023, where net earnings drop to 4,863 million USD, followed by a further decrease in 2024 to 4,278 million USD.
Similarly, net operating profit after taxes (NOPAT) exhibits a strong growth trajectory in the initial years, rising from 4,455 million USD in 2020 to 12,362 million USD in 2021, before slightly decreasing to 11,543 million USD in 2022. In contrast to the early upward momentum, NOPAT experiences a significant fall in 2023 to 3,292 million USD, although it recovers somewhat in 2024 to 4,563 million USD.
- Net Earnings Attributable to the Company
- Demonstrated substantial growth in the first two years, peaking in 2022.
- Experienced a pronounced decline in the subsequent years, reaching the lowest point in 2024 within the presented timeframe.
- Net Operating Profit After Taxes (NOPAT)
- Followed a similar pattern to net earnings, with rapid growth through 2021, slight reduction in 2022.
- Showed a sharp decline beginning in 2023, with modest recovery in 2024 albeit remaining well below earlier peak levels.
Overall, the data points toward a period of strong profitability gains up to 2022, followed by notable erosion in both net earnings and NOPAT over the last two years. The decline in profitability metrics during 2023 and 2024 suggests the presence of operational challenges or market conditions adversely impacting financial performance. The partial resurgence of NOPAT in 2024 hints at potential stabilization or early signs of financial recovery.
Cash Operating Taxes
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
- Income Tax Expense (Benefit) Trend
- The income tax expense exhibited significant volatility over the analyzed period. It began with a notable benefit of -$1,224 million at the end of 2020, indicating a tax gain or credit that reduced tax burden during that year. This reversed sharply in 2021 to a tax expense of $1,440 million, then further increased to $1,632 million in 2022. In 2023, it slightly decreased but remained high at $1,377 million. However, in 2024, the income tax expense again turned negative, showing a benefit of -$570 million. This pattern suggests fluctuating tax positions or adjustments possibly due to changes in tax regulations, earnings variations, or deferred tax accounting impacts.
- Cash Operating Taxes Trend
- The cash operating taxes consistently increased from 2020 through 2023, indicating increasing cash payments for taxes despite fluctuations in reported income tax expense. In 2020, cash taxes were $1,585 million, which rose significantly each year to reach $4,625 million in 2023. However, in 2024, there was a notable decline in cash operating taxes to $1,339 million, which is substantially lower than the prior years. This decline could suggest a one-time tax payment adjustment, changes in taxable income, tax credits utilization, or other operational tax strategies impacting cash outflows.
- General Observations
- While reported income tax expenses fluctuated between benefits and expenses, cash taxes paid showed a general increasing trend until a sharp drop in 2024. The divergence between income tax expense and cash operating taxes through the years implies differences between accounting recognition of tax expenses and actual tax payments, which is common in companies with complex tax structures. The decline in both income tax expense and cash operating taxes in 2024 may indicate significant tax planning outcomes or shifts in profitability affecting tax liabilities.
Invested Capital
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Addition of capitalized operating leases.
2 Elimination of deferred taxes from assets and liabilities. See details »
3 Addition of restructuring reserve.
4 Addition of equity equivalents to stockholders’ equity.
5 Removal of accumulated other comprehensive income.
6 Subtraction of construction in progress.
7 Subtraction of available-for-sale investment securities.
The financial data over the provided periods reveal several significant trends related to debt, equity, and capital structure.
- Total reported debt & leases
- The total reported debt and leases exhibit a decreasing trend from 87,063 million USD at the end of 2020 to 60,286 million USD by the end of 2023, reflecting a substantial reduction in leverage over the first four years. However, in 2024, there is a noticeable increase to 68,019 million USD, indicating a reversal of the prior downward trend in debt levels.
- Stockholders’ equity
- Stockholders' equity initially increases from 13,076 million USD in 2020 to a peak of 17,254 million USD in 2022. Subsequently, it declines sharply to 10,360 million USD in 2023 and continues to deteriorate significantly in 2024, dropping to 3,325 million USD. This steep decrease in equity over the last two years suggests increased challenges with retained earnings or potential capital losses.
- Invested capital
- Invested capital shows a consistent downward trajectory, reducing from 103,725 million USD in 2020 to 68,204 million USD in 2023. Unlike other trends, invested capital appears to stabilize in 2024 with a slight increase to 69,263 million USD, signaling a possible floor or minor recovery in invested assets or operational capital use.
Overall, the data suggest a focused effort on debt reduction from 2020 to 2023 accompanied by increasing equity till 2022. However, the last two years highlight financial stress with declining equity and rising debt, raising concerns about the company’s capital structure stability and financial leverage. The decline and subsequent stabilization in invested capital corroborate a contraction phase followed by an attempt to maintain or increment operational investment.
Cost of Capital
AbbVie Inc., cost of capital calculations
Capital (fair value)1 | Weights | Cost of capital | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity2 | ÷ | = | × | = | |||||||||
Debt and finance lease obligations3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
Total: |
Based on: 10-K (reporting date: 2024-12-31).
1 US$ in millions
2 Equity. See details »
3 Debt and finance lease obligations. See details »
4 Operating lease liability. See details »
Capital (fair value)1 | Weights | Cost of capital | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity2 | ÷ | = | × | = | |||||||||
Debt and finance lease obligations3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
Total: |
Based on: 10-K (reporting date: 2023-12-31).
1 US$ in millions
2 Equity. See details »
3 Debt and finance lease obligations. See details »
4 Operating lease liability. See details »
Capital (fair value)1 | Weights | Cost of capital | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity2 | ÷ | = | × | = | |||||||||
Debt and finance lease obligations3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
Total: |
Based on: 10-K (reporting date: 2022-12-31).
1 US$ in millions
2 Equity. See details »
3 Debt and finance lease obligations. See details »
4 Operating lease liability. See details »
Capital (fair value)1 | Weights | Cost of capital | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity2 | ÷ | = | × | = | |||||||||
Debt and finance lease obligations3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
Total: |
Based on: 10-K (reporting date: 2021-12-31).
1 US$ in millions
2 Equity. See details »
3 Debt and finance lease obligations. See details »
4 Operating lease liability. See details »
Capital (fair value)1 | Weights | Cost of capital | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity2 | ÷ | = | × | = | |||||||||
Debt and finance lease obligations3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
Total: |
Based on: 10-K (reporting date: 2020-12-31).
1 US$ in millions
2 Equity. See details »
3 Debt and finance lease obligations. See details »
4 Operating lease liability. See details »
Economic Spread Ratio
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Economic profit1 | ||||||
Invested capital2 | ||||||
Performance Ratio | ||||||
Economic spread ratio3 | ||||||
Benchmarks | ||||||
Economic Spread Ratio, Competitors4 | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Economic profit. See details »
2 Invested capital. See details »
3 2024 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =
4 Click competitor name to see calculations.
- Economic Profit Trend
- The economic profit experienced significant fluctuations over the analyzed period. In 2020, the company reported a negative economic profit of -3,673 million US dollars, which turned positive and improved markedly to 4,064 million US dollars in 2021. This positive trend continued slightly in 2022 with 3,942 million US dollars. However, in 2023, the figure reversed sharply to a negative value of -3,166 million, and although there was some recovery in 2024, economic profit remained negative at -2,027 million. This pattern indicates volatility and challenges in sustaining value creation in recent years.
- Invested Capital Movement
- Invested capital showed a consistent decline from 2020 to 2023, falling from 103,725 million US dollars to 68,204 million US dollars, representing a substantial reduction in the capital base. In 2024, a slight increase was observed, bringing invested capital to 69,263 million US dollars. Overall, the trend suggests a significant scaling down or more efficient use of capital over the period.
- Economic Spread Ratio Analysis
- The economic spread ratio, representing the difference between return on invested capital and cost of capital, mirrored the economic profit trend. It was negative in 2020 at -3.54%, turned positive in 2021 at 4.24%, and increased further to 4.80% in 2022, signaling improved profitability relative to cost. However, the ratio reversed into negative territory again in 2023 at -4.64%, followed by a less negative figure of -2.93% in 2024. This indicates a struggle to maintain profitability above the cost of capital in the latter years of the period.
- Overall Financial Performance Insights
- The data reflect a cyclical pattern in financial performance, with a pronounced improvement in 2021 and 2022 followed by a substantial decline in 2023 and partial recovery in 2024. The reduction in invested capital is notable and may relate to strategic reallocations or asset divestments aimed at improving capital efficiency. Nonetheless, the reemergence of negative economic spread and economic profit in recent years suggests ongoing challenges in generating returns that exceed capital costs. The company’s financial health, therefore, appears to be in a state of adjustment, warranting close monitoring of both profitability metrics and capital management strategies.
Economic Profit Margin
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Economic profit1 | ||||||
Net revenues | ||||||
Performance Ratio | ||||||
Economic profit margin2 | ||||||
Benchmarks | ||||||
Economic Profit Margin, Competitors3 | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Economic profit. See details »
2 2024 Calculation
Economic profit margin = 100 × Economic profit ÷ Net revenues
= 100 × ÷ =
3 Click competitor name to see calculations.
- Economic Profit
- The economic profit exhibited significant fluctuations over the five-year period. Initially, there was a substantial negative value of -3673 million US dollars at the end of 2020, which sharply improved to a positive 4064 million in 2021 and remained relatively stable at 3942 million in 2022. However, in 2023, the figure reverted to negative territory at -3166 million, followed by a less negative value of -2027 million in 2024. This pattern indicates oscillating profitability with marked improvement in 2021 and 2022, but a return to losses thereafter, albeit with a decreasing negative trend into 2024.
- Net Revenues
- Net revenues demonstrated an overall upward trend during the period analyzed. Revenues increased from 45,804 million US dollars in 2020 to a peak of 58,054 million in 2022, showing strong growth. Despite a drop to 54,318 million in 2023, revenues rebounded to 56,334 million in 2024. This indicates resilience and effective revenue generation capabilities, with a temporary decline in 2023 that was partially recovered by the following year.
- Economic Profit Margin
- The economic profit margin mirrored the fluctuations observed in economic profit. Starting at a negative -8.02% in 2020, the margin improved substantially to positive values of 7.23% in 2021 and 6.79% in 2022, indicating increased efficiency and profitability during these years. However, the margin fell back into negative figures in 2023 and 2024, recording -5.83% and -3.6%, respectively. Despite this decline, the less negative margin in 2024 compared to 2023 suggests a potential for recovery.